CD274 and melanoma: Additionally, based on the interactions between circulation exosomal PD-L1 and T cells, it has been reported in melanoma patients that tracking the levels of circulating exosomal PD-L1 may help to predict a patient’s response to anti-PD-L1 therapy (pembrolizumab) [7].